Latest news with #JournalforImmunoTherapyofCancer
Yahoo
4 days ago
- Business
- Yahoo
Minerva Biotechnologies - Overcoming the Solid Tumor Barrier: MUC1*-Targeted CAR T bearing 1XX mutations overcomes exhaustion and enables killing of low antigen expressing cancer cells
WALTHAM, Mass., June 02, 2025--(BUSINESS WIRE)--Minerva Biotechnologies published "Effective CAR T cell targeting of a MUC1 cleavage product" in the Journal for ImmunoTherapy of Cancer Novel target, MUC1*, is a cancer-specific growth factor receptor that is expressed on the surface of 75% of solid tumors. In this study, we compared the efficacy, persistence and antigen sensitivity of three MUC1* CARs, all directed to the tumor by the same antibody fragment, but bearing different co-stimulatory domains and one construct bearing the 1XX mutations in the CD3ζ cytoplasmic domain. We showed that in animal models, the MUC1* CAR-1XX increased CAR T-cell persistence and suppressed tumor recurrence by enabling the killing of low antigen-expressing cancer cells. "These findings in stringent animal models are very encouraging for developing 1XX CAR T cells to treat solid tumors," said Michel Sadelain, inventor of the 1XX technology. "They further underscore the promise of targeting the cleaved form of MUC1 known as MUC1*." The in vivo efficacy of MUC1* targeted CAR-1XX T cells against heterogeneous tumors comprising defined percentages of low vs high antigen expressing cancer cells predicts that a large patient population could be treated with MUC1* targeted CAR T immunotherapy. Although MUC1 has been known for 30 years to be aberrantly expressed in 75% of solid tumors, no therapeutic targeting MUC1 has ever been Food and Drug Administration approved. Part of the problem is that the identification of exactly which form of MUC1 drives tumor growth and metastasis has been controversial. The development of a MUC1* antibody that selectively recognizes the cancer-associated growth factor receptor form, as described here, is an important advance. Minerva has an FDA-approved IND for a MUC1*-CAR22 that persists longer in vivo enabling a more durable response in solid tumor treatment. We thank Memorial Sloan Kettering Cancer Center for the license to 1XX technology. View source version on Contacts Minerva Biotechnologies Ron Axelrod raxelrod@ 617-785-9491 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
4 days ago
- Health
- Business Wire
Minerva Biotechnologies - Overcoming the Solid Tumor Barrier: MUC1*-Targeted CAR T bearing 1XX mutations overcomes exhaustion and enables killing of low antigen expressing cancer cells
WALTHAM, Mass.--(BUSINESS WIRE)--Minerva Biotechnologies published 'Effective CAR T cell targeting of a MUC1 cleavage product' in the Journal for ImmunoTherapy of Cancer Novel target, MUC1*, is a cancer-specific growth factor receptor that is expressed on the surface of 75% of solid tumors. In this study, we compared the efficacy, persistence and antigen sensitivity of three MUC1* CARs, all directed to the tumor by the same antibody fragment, but bearing different co-stimulatory domains and one construct bearing the 1XX mutations in the CD3ζ cytoplasmic domain. We showed that in animal models, the MUC1* CAR-1XX increased CAR T-cell persistence and suppressed tumor recurrence by enabling the killing of low antigen-expressing cancer cells. 'These findings in stringent animal models are very encouraging for developing 1XX CAR T cells to treat solid tumors,' said Michel Sadelain, inventor of the 1XX technology. 'They further underscore the promise of targeting the cleaved form of MUC1 known as MUC1*." The in vivo efficacy of MUC1* targeted CAR-1XX T cells against heterogeneous tumors comprising defined percentages of low vs high antigen expressing cancer cells predicts that a large patient population could be treated with MUC1* targeted CAR T immunotherapy. Although MUC1 has been known for 30 years to be aberrantly expressed in 75% of solid tumors, no therapeutic targeting MUC1 has ever been Food and Drug Administration approved. Part of the problem is that the identification of exactly which form of MUC1 drives tumor growth and metastasis has been controversial. The development of a MUC1* antibody that selectively recognizes the cancer-associated growth factor receptor form, as described here, is an important advance. Minerva has an FDA-approved IND for a MUC1*-CAR22 that persists longer in vivo enabling a more durable response in solid tumor treatment. We thank Memorial Sloan Kettering Cancer Center for the license to 1XX technology.
Yahoo
29-01-2025
- Business
- Yahoo
Alligator Bioscience Announces Publication of Clinical Data for ATOR-1017 (evunzekibart) in the Journal for ImmunoTherapy of Cancer
LUND, SE / / January 29, 2025 / Alligator Bioscience (STO:ATORX) Publication validates encouraging clinical safety and tolerability in this first-in-human trial Data show early signs of clinical efficacy in patients with advanced cancer Pharmacokinetic and pharmacodynamic analyses demonstrate proof of mechanism for ATOR-1017 Lund, Sweden - Alligator Bioscience (Nasdaq Stockholm:ATORX) today announces that clinical data for its 4-1BB agonist, ATOR-1017, has been published in the Journal for ImmunoTherapy of Cancer (JITC). This publication validates ATOR-1017's safety and tolerability in patients with advanced cancers and highlights early signs of clinical efficacy. Additionally, pharmacokinetic and pharmacodynamic analyses demonstrate proof of mechanism, further supporting the therapeutic potential of ATOR-1017. This publication adds to previously published preclinical data and underscores the scientific foundation of ATOR-1017 as an immunotherapy designed to activate T cells and natural killer (NK) cells in a tumor-specific manner. These findings strengthen the clinical package for ATOR-1017 and support its potential for future development, particularly in combination with other anticancer agents. Dr. Sumeet Ambarkhane, Chief Medical Officer of Alligator Bioscience, commented:"These first-in-human clinical data of ATOR-1017 in the Journal for ImmunoTherapy of Cancer demonstrate excellent safety profile and biological activity ATOR-1017. This peer-reviewed publication also reaffirms the scientific value of targeting 4-1BB pathway as a cancer immunotherapy, and further enhances its potential for future development." Alligator remains focused on advancing its lead candidate, mitazalimab, while exploring strategic opportunities to realize the potential of ATOR-1017. For further information, please contact: Søren Bregenholt, CEOE-mail: +46 (0) 46 540 82 00 About Alligator Bioscience Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. This validated approach promotes priming of tumor-specific T cells and reversing the immunosuppressive nature of the tumor microenvironment, with significant potential benefits for cancer patients across multiple types of cancer. The Company's lead drug candidate mitazalimab, is currently in preparation for Phase 3 development, and has previously presented unprecedented survival data at 18-months follow up in first-line metastatic pancreatic cancer patients in the Phase 2 trial OPTIMIZE-1. Alligator is listed on Nasdaq Stockholm (ATORX) and headquartered in Lund, Sweden. For more information, please visit Attachments Alligator Bioscience Announces Publication of Clinical Data for ATOR-1017 (evunzekibart) in the Journal for ImmunoTherapy of Cancer SOURCE: Alligator Bioscience View the original press release on ACCESS Newswire Sign in to access your portfolio
